Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage
NCT03390530 · Albert Einstein College of Medicine · PHASE3 · withdrawn · last registry update 2022-07-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Closed by PI prior to approval” | – | Registry record, Albert Einstein College of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against THRA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-06-08Phase 3 first posted: Privo Technologies, PRV211 (Intraoperative Cisplatin System) + PRV111 (Cisplatin Transmucosal System) (NCT05893888)
- 2023-06-08Phase 3 first posted: Alzheimer's Prevention and Reversal Project, Inc., Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises (NCT05894954)
- 2023-01-12Phase 3 first posted: M. Medici, LT3 (liothyronine) + Placebo (NCT05682482)
- 2022-10-13Phase 3 first posted: Rare Thyroid Therapeutics International AB, Tiratricol + Placebo (NCT05579327)
- 2021-07-16Phase 3 first posted: Suzhou Zelgen Biopharmaceuticals Co.,Ltd, rhTSH (NCT04964284)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision